Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Razaxaban
General information
Razaxaban, a selective oral direct factor Xa inhibitor [ , ], was discontinued by the manufacturer after the three higher doses in a dose-ranging study in venous thromboembolism caused an increased risk of bleeding.
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here